Wuhan Keqian Biology Co.,Ltd: history, ownership, mission, how it works & makes money

Founded in 2001, Wuhan Keqian Biology Co., Ltd. (listed on the STAR Market as 688526.SS) has grown from an R&D-focused veterinary biologics startup into a debt-free, publicly traded animal-health company with a market capitalization of about 7.16 billion yuan and 463.92 million shares outstanding; after reporting 941.92 million yuan in revenue for 2024 (down 11.48% year‑on‑year), Keqian surged in the first half of 2025 with 487 million yuan in revenue (+21.67% YoY) and a net profit of 220 million yuan (+44.09% YoY), driven by high gross and operating margins (61.74% and 34.62%), an EPS of 0.87 yuan, an annual dividend of 0.43 yuan (yield 2.70%), and a pristine balance sheet (current ratio 5.32, debt-to-equity 0.00) that supports its mission to become a world-class animal‑health enterprise; the firm - headquartered in Wuhan with 924 employees, recognized as a National Enterprise Technology Center in 2020, led by an R&D team including academicians and boasting awards at national and provincial levels - monetizes vaccines, diagnostic reagents and prevention services, recently won regulatory approval for a Mycoplasma bovis live vaccine in August 2025 and agreed in December 2025 to co-own two vaccine rights with Huazhong Agricultural University for 3.4 million yuan, while market metrics (EV 6.10 billion yuan, EV/EBITDA 13.61, trailing P/E 18.30, forward P/E 16.68, ROE 10.09%, ROIC 5.20% and a 52-week stock gain of 23.45%) and an average 12-month price target of 21.75 yuan frame the near-term outlook.

Wuhan Keqian Biology Co.,Ltd (688526.SS): Intro

• Founded: 2001
• Listing: STAR Market, Shanghai Stock Exchange (2020), code 688526
• Primary products: Veterinary vaccines (live, inactivated), diagnostic reagents, bioproducts

• Early years (2001-2010): Built R&D and production capabilities for animal vaccines and reagents.
• Expansion (2010-2019): Scaled manufacturing, broadened product portfolio for pigs, poultry and companion animals.
• Public listing (2020): Access to capital via STAR Market to fund R&D, capacity expansion, and regulatory approvals.
• Recent approvals & partnerships (2024-2025): Revenue pressure in 2024 followed by margin recovery and product approvals in 2025.

• Publicly traded entity on Shanghai STAR Market (688526.SS), with institutional and retail shareholders.
• Operate under a board of directors and executive management focused on veterinary biotech R&D commercialization.
• Collaborative IP arrangements with academic institutions (e.g., Huazhong Agricultural University)

• Mission: Improve animal health and production efficiency through innovative, safe veterinary biological products.
• R&D priorities: Vaccine development (including live and inactivated vaccines), diagnostics for major livestock pathogens, and product approvals aligned with Chinese regulatory authorities.

• Product sales: Vaccines (core revenue driver), diagnostic reagents, and ancillary animal health products to farms, veterinary clinics, and distributors.
• Licensing & collaborations: Technology transfer, co-ownership agreements (e.g., 3.4 million yuan deal with Huazhong Agricultural University in Dec 2025) and licensing fees.
• Government & institutional procurement: Sales driven by national and local livestock disease control programs, supported by regulatory approvals (e.g., Mycoplasma bovis live vaccine approved Aug 2025).
• R&D grants and subsidies: Funding for innovative products and registration processes.

• Aug 2025: Mycoplasma bovis live vaccine approval expands addressable market in cattle and contributes to future sales growth.
• Dec 2025: Co-ownership with Huazhong Agricultural University for two vaccines (pigs and dogs) signals continued pipeline commercialization and technology monetization.
• H1 2025 financials indicate operational recovery with significant net profit growth despite 2024 revenue decline.

Wuhan Keqian Biology Co.,Ltd (688526.SS): History

• Founded with a focus on molecular diagnostics and reagent manufacturing.
• Scaled through product approvals, strategic production capacity expansion, and adoption by clinical laboratories.
• Publicly listed and capitalized to invest in automated platforms and reagent development.

• Shares outstanding: 463.92 million.
• Market capitalization: ~7.16 billion yuan.
• Insider ownership: 59.65% of shares.
• Institutional ownership: 5.33% of shares.

• Mission: deliver accurate, scalable molecular diagnostic solutions and life-science reagents to clinical and research labs.
• Strategic priorities: expand reagent pipelines, improve automation, and broaden domestic and export market penetration.

• Product sales: primary revenues from diagnostic kits (nucleic acid, immunoassays) and consumables sold to hospitals, CDCs, and third‑party labs.
• Platform and instrument sales: automated analyzers and complementary reagents-often sold as a combination of hardware and recurring consumable sales.
• OEM/contract manufacturing: leveraging production capacity to produce reagents for other brands or partners.
• R&D and service contracts: collaborative development and testing services for institutional partners.

Wuhan Keqian Biology Co.,Ltd (688526.SS): Ownership Structure

• Mission: Become a world-class enterprise in animal health focused on creating national premium brands and protecting livestock sustainability and human health.
• Core values: 'Create value through science and technology, repay society with science and technology.'
• Spirit & attitude: 'Innovation, creation, entrepreneurship' and 'loyalty, enterprising, rigorous, pragmatic.'
• Strategic commitment: Sustainable development of stock breeding, disease prevention, and improving public health through veterinary solutions.

• R&D-driven product pipeline focused on veterinary biologics, vaccines, diagnostics and feed additives; commercialization through direct sales and distribution networks.
• Revenue streams: product sales (vaccines, biologics), technical service and OEM partnerships, and licensing of technology where applicable.
• Investment in innovation and certification (e.g., National Enterprise Technology Center in 2020) to improve margins and expand high-value product offerings.

Wuhan Keqian Biology Co.,Ltd (688526.SS): Mission and Values

• R&D-led product development: Keqian develops vaccines and diagnostic reagents through in-house research teams led by academicians and senior scientists, translating lab discoveries into registered veterinary products.
• Manufacturing: The company operates GMP-compliant production facilities to produce inactivated and recombinant vaccines, antigen/antibody reagents and related formulations for animals.
• Regulatory & quality assurance: Keqian navigates national veterinary drug registration and quality inspections, maintaining product dossiers and lot-release compliance for domestic and (where applicable) export markets.
• Sales & distribution: Products are sold through a combination of direct sales to large farms and integrators, distributor networks for regional coverage, and institutional channels (government and public animal-health programs).
• Technical services & epidemic prevention: Field technical teams provide vaccination programs, cold-chain support, diagnostic testing and epidemic-response services to customers.

• Pig vaccines: classical swine fever, porcine reproductive and respiratory syndrome (PRRS) variants, swine erysipelas and other common porcine immunizations.
• Poultry vaccines: avian influenza, Newcastle disease, infectious bronchitis and combination vaccines for commercial flocks.
• Pet vaccines & biologics: core vaccines and immunological reagents for companion animals.
• Diagnostic reagents: ELISA kits, rapid tests and laboratory reagents for disease surveillance and herd/flock health monitoring.

• R&D leadership: a technical team led by academicians and senior researchers driving innovation and regulatory submissions.
• Awards: Recipient of 2 second prizes of the National Science and Technology Progress Award and 5 first prizes of the Hubei Science and Technology Progress Award, demonstrating recognized contributions to veterinary science and technology.
• Workforce: 924 employees across R&D, production, quality, sales and field service functions.

• Product sales: recurring revenue from routine vaccination programs in commercial pig and poultry production and companion-animal clinics.
• Institutional contracts: large-scale procurement by integrators, government immunization campaigns and emergency epidemic-response contracts.
• Diagnostic & reagent sales: one-time and repeat purchases by diagnostic labs, veterinary hospitals and farm-health programs.
• Technical services: paid epidemic prevention services, vaccination campaigns and field technical support that complement product sales.
• Pipeline and licensing: potential milestone or licensing revenue from joint development of novel biologics or technology transfer agreements.

• Vertical integration reduces time from R&D to market and helps capture margin across development, manufacturing and field service delivery.
• Regulatory approvals and national-level awards enhance credibility with large customers and increase chances of inclusion in public procurement lists.
• Sales mix depends on seasonal disease cycles, livestock herd sizes, and government-driven vaccination programs; epidemic outbreaks can materially increase near-term demand for vaccines and diagnostics.

Wuhan Keqian Biology Co.,Ltd (688526.SS): How It Works

• Core revenue streams: commercial sales of veterinary vaccines (multiple species) and diagnostic reagent kits.
• Value drivers: proprietary antigen technologies, large-scale GMP production, and established veterinarian and distributor relationships.
• R&D pipeline: iterative upgrade of vaccine strains and diagnostic reagents to address emerging animal diseases and improve efficacy.
• Sales channels: direct sales to large animal farms, distributors, veterinary clinics, and institutional procurement.

• High-margin proprietary vaccines drive gross margin (61.74%).
• Efficient production and scaled operations support an operating margin of 34.62%.
• Strong profitability growth: net profit rose 44.09% YoY in H1 2025, reflecting volume growth and margin expansion.

• Manufacturing: GMP-compliant facilities that lower per-unit cost at scale.
• Quality/regulatory: approvals and batch release processes enabling market access.
• Commercial: sales teams and distributor networks converting product availability into recurring orders.
• After-sales: diagnostic reagents and support services that encourage repeat purchasing.

Wuhan Keqian Biology Co.,Ltd (688526.SS): How It Makes Money

• Primary revenue streams: sale of reagents and consumables for molecular diagnostics and life-science research.
• Secondary revenue: instrument sales, OEM partnerships, and after-sales service contracts.
• Recurring revenue from long-term supply agreements with hospitals, research institutes, and distributors.

• High-margin consumables: single-use reagents and kits sold at scale to clinical and research customers.
• Platform instruments: one-time sales with attached consumable lifetime revenue.
• Contract manufacturing & OEM: bespoke production for larger diagnostics firms, boosting utilization and margin stability.
• Service & maintenance: installed-base contracts provide predictable recurring income and customer lock-in.

• Solid balance sheet-current ratio 5.32 and zero reported debt-supports R&D and capacity expansion.
• Valuation metrics (trailing P/E 18.30; forward P/E 16.68) imply moderate growth expectations priced by the market.
• ROE of 10.09% and ROIC of 5.20% indicate profitable operations with room to improve capital efficiency as scale increases.
• Stock momentum (up 23.45% over 52 weeks) and analyst price targets (avg 21.75 yuan) reflect investor optimism for continued top-line growth and margin expansion.